Search results for " Systemic"

showing 10 items of 201 documents

Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames)

2017

Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). Methods Patients with SSc‐related RP were randomized 1:1 to placebo (n = 38) or selexipag (n = 36) in individualized doses (maximum of 1,600 μg twice daily) during a 3‐week titration period. The primary end point was the weekly average number of RP attacks during the study maintenance period, analyzed using a Bayesian approach with a negative binomial model adjusted for baseline number of RP attacks. Other outcome measures included Raynaud's Condition Score (RCS), RP attack duration, and treat…

Adultmedicine.medical_specialtymedicine.drug_classImmunologyIschemiaSystemic SclerosisCalcium channel blockerScleroderma03 medical and health sciences0302 clinical medicineRheumatologyAcetamidesmedicineHumansImmunology and Allergy030212 general & internal medicineskin and connective tissue diseasesIntensive care medicine030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryVascular diseaseRaynaud DiseaseVasospasmmedicine.diseaseSurgeryClinical trialPyrazinesPillOriginal ArticleSugarsbusinessVasodilating AgentArthritis & Rheumatology
researchProduct

Contagion and Bank Runs in a Multi-Agent Financial System

2012

In this work we explore contagion from one institution to another that can stem from the existence of a network of financial contracts. In fact, in modern financial systems, an intricate web of claims and obligations links the balance sheets of a wide variety of intermediaries (banks, for instance) into a network structure of interdependencies that have created an environment for feedback elements to generate amplified responses to shocks to the financial system. Small shocks, which initially affect only a few institutions, can indeed spread by contagion to the rest of the financial sector and cause a crisis in the connected intermediaries. Whether the financial crisis does spread depends c…

Agent-based modelComplex contagionFinancial networksmedia_common.quotation_subjectBank runFinancial systemherding behaviorSettore SECS-S/06 -Metodi Mat. dell'Economia e d. Scienze Attuariali e Finanz.systemic riskSystemic riskInstitutionbank runDeposit insuranceBalance sheetBusinessContagion financial network systemic risk agent based model.media_common
researchProduct

Immunoregulatory role of Jα281 T cells in aged mice developing lupus-like nephritis

2007

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the emergence of autoreactive T cells. Humans and mice with SLE have reduced numbers of CD1d-restricted invariant natural killer T (iNKT) cells, suggesting a key role for these cells in its immunopathogenesis. This subset uses an invariant TCR constituted by Valpha14 Jalpha281 chains paired with some Vbeta domains. The regulatory role for iNKT cells in non-autoimmune mice was suggested by our previous results showing that aged Jalpha281 knockout (KO) mice produce anti-dsDNA. Here we show that old Jalpha281 KO mice have proteinuria and antibodies against dsDNA and cardiolipin. Histological analysis of Jalpha281 KO m…

AgingImmunologyReceptors Antigen T-CellEnzyme-Linked Immunosorbent AssayLymphocyte Activationmedicine.disease_causeAutoimmunity Knockout NKT cellsAutoimmunityMicemedicineAnimalsLupus Erythematosus SystemicImmunology and AllergyAutoantibodiesMice KnockoutSettore MED/04 - Patologia GeneraleB-LymphocytesSystemic lupus erythematosusbiologyT-cell receptorAutoantibodyNatural killer T cellMarginal zonemedicine.diseaseImmunohistochemistryLupus NephritisKiller Cells NaturalImmunologybiology.proteinAntibodyNephritisSpleenEuropean Journal of Immunology
researchProduct

Heart Valve Abnormalities in Systemic Sclerosis Patients; A Multicenter Cohort Study and Review of the Literature

2020

Background Systemic sclerosis (SSc) is a chronic autoimmune disease that is characterized by vasculopathy and fibrosis of the skin and visceral organs. Heart valve diseases are poorly described and generally not considered typical of SSc. We aimed to describe valvular abnormalities in a multicenter cohort of SSc patients and to investigate their correlation with SSc features. Methods We recruited 118 consecutive SSc patients (male/female, 14/104; mean age, 55.2 ± 12.1 years) in 3 rheumatology centers in Sicily, Italy, from January to October 2019. Results Mitral and tricuspid valve insufficiency was found in 85% and 91% of patients, respectively; regurgitations were generally mild and never…

Aortic valveAdultMalemedicine.medical_specialtyHeart Valve DiseasesTricuspid stenosisSclerodermaCohort Studies03 medical and health sciences0302 clinical medicineRheumatologyTricuspid Valve InsufficiencyMitralInternal medicineMedicineHumansMulticenter Studies as Topiccardiovascular diseases030212 general & internal medicineHeart valveAortic valveskin and connective tissue diseasesAged030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industrySystemicMitral Valve InsufficiencyMiddle Agedmedicine.diseaseValvular diseaseHeart ValvesRheumatologyTricuspid Valve InsufficiencyStenosismedicine.anatomical_structurePulmonary valvecardiovascular systemCardiologySystemic sclerosisFemalebusinessTricuspidCohort study
researchProduct

Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors

2022

Background: The combination of atezolizumab-bevacizumab has been proven to be superior to sorafenib for the treatment of unresectable hepatocellular carcinoma not amenable to locoregional treatments, be-coming the standard of care of systemic therapy.Aim: This study aimed at assessing real-world feasibility of atezolizumab-bevacizumab in patients treated with tyrosine-kinase inhibitors.Methods: Among 1447 patients treated with tyrosine-kinase inhibitors from January 2010 to December 2020, we assessed the percentage of those potentially eligible to atezolizumab-bevacizumab (according to IMbrave-150 trial criteria), and the overall survival of eligible and non-eligible patients.Results: 422 (…

Atezolizumab-bevacizumabClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolCarcinoma HepatocellularSystemic therapyHepatologyHepatocellular carcinomaTirosin-kinase inhibitorLiver NeoplasmsGastroenterologyTirosin-kinase inhibitor.Atezolizumab-bevacizumab; Hepatocellular carcinoma; Systemic therapy; Tirosin-kinase inhibitorBevacizumabFeasibility StudieTyrosineHumanDigestive and Liver Disease
researchProduct

Genetics and novel aspects of therapies in systemic lupus erythematosus.

2015

Autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, autoimmune hepatitis and inflammatory bowel disease, have complex pathogeneses and the factors which cause these disorders are not well understood. But all have in common that they arise from a dysfunction of the immune system, interpreting self components as foreign antigens. Systemic lupus erythematosus (SLE) is one of these complex inflammatory disorders that mainly affects women and can lead to inflammation and severe damage of virtually any tissue and organ. Recently, the application of advanced techniques of genome-wide scanning revealed more genetic information about SLE than previously possible. These case-contro…

Autoimmune diseaseMultiple sclerosisImmunologyGenome-wide association studyAutoimmune hepatitisBiologymedicine.diseaseInflammatory bowel diseaseImmune systemAutologous stem-cell transplantationTreatment OutcomeRheumatoid arthritisHistocompatibility AntigensImmunologymedicineImmunology and AllergyAnimalsHumansLupus Erythematosus SystemicGenetic Predisposition to Diseaseskin and connective tissue diseasesImmunosuppressive AgentsGenome-Wide Association StudyAutoimmunity reviews
researchProduct

2013 ECONOMY MOMENTUM CHALLENGES FOR NEXT 10 YEARS

2013

Last 5 years of almost unprecedented financial market turmoil it s still generating comprehensive crisis theories, market paradigms and nevertheless unprecedented situations. The aim of this paper is to explain 2013 milestone momentum for new market rules and regulations implementation - Basel III. The expected immediate cushion factors as well the possible negative impact on financial markets is presented from financial institutions perspective. Finally, the paper seeks for an exploratory after 10 years scenario connected with imminent market evolution and tendencies.

Basel III systemic risk sovereign debt crisis risk capitalRevista Economica
researchProduct

Minor changes in the macrocyclic ligands but major consequences on the efficiency of gold nanoparticles designed for radiosensitization

2016

International audience; Many studies have been devoted to adapting the design of gold nanoparticles to efficiently exploit their promising capability to enhance the effects of radiotherapy. In particular, the addition of magnetic resonance imaging modality constitutes an attractive strategy for enhancing the selectivity of radiotherapy since it allows the determination of the most suited delay between the injection of nanoparticles and irradiation. This requires the functionalization of the gold core by an organic shell composed of thiolated gadolinium chelates. The risk of nephrogenic systemic fibrosis induced by the release of gadolinium ions should encourage the use of macrocyclic chelat…

BiodistributiontumorMaterials scienceGadoliniumchemistry.chemical_elementNanoparticleContext (language use)Nanotechnology02 engineering and technology[CHIM.THER]Chemical Sciences/Medicinal Chemistry010402 general chemistry01 natural sciences[ CHIM ] Chemical Sciencesnephrogenic systemic fibrosis[CHIM]Chemical SciencesGeneral Materials ScienceChelationratbiodistributionradiotherapyrenal clearance[ CHIM.THER ] Chemical Sciences/Medicinal Chemistry021001 nanoscience & nanotechnologyCombinatorial chemistry0104 chemical scienceschemistrymri contrast agentsColloidal goldSurface modification0210 nano-technologySelectivitydihydrolipoic acidmicrobeam radiation-therapy9l gliosarcoma
researchProduct

Label-free piezoelectric biosensor for prognosis and diagnosis of Systemic Lupus Erythematosus

2017

[EN] An autoantigen piezoelectric sensor to quantify specific circulating autoantibodies in human serum is developed. The sensor consisted on a quartz crystal microbalance with dissipation monitoring (QCM-D) where TRIM21 and TROVE2 autoantigens were covalently immobilized, allowing the selective determination of autoantibodies for diagnosis and prognosis of Systemic Lupus Erythematosus (SLE). The sensitivity of the biosensor, measured as IC50 value, was 1.51 U/mL and 0.32 U/mL, for anti-TRIM21 and anti-TROVE2 circulating autoantibodies, respectively. The sensor is also able to establish a structural interaction fingerprint pattern or profile of circulating autoantibodies, what allows scorin…

Biomedical EngineeringBiophysicsEarly detectionBiosensing Techniques02 engineering and technologyImmunosensorDissipation monitoringAutoantigensSensitivity and SpecificitySystemic Lupus Erythematosus01 natural sciencesQuartz crystal microbalanceRNA Small CytoplasmicDiagnosisQUIMICA ANALITICAElectrochemistryHumansLupus Erythematosus SystemicMedicineMultiplexPiezoelectric biosensorAutoantibodiesLabel freeRibonucleoproteinbusiness.industry010401 analytical chemistryAutoantibodyGeneral MedicineQuartz crystal microbalancePrognosis021001 nanoscience & nanotechnology0104 chemical sciencesInteraction fingerprintRibonucleoproteinsImmunologyQuartz Crystal Microbalance Techniques0210 nano-technologybusinessBiosensorBiotechnologyBiosensors and Bioelectronics
researchProduct

Anti-C1q Autoantibodies in Lupus Nephritis: Prevalence and Clinical Significance

2005

Recently, anti-C1q autoantibodies have been proposed as a useful marker in systemic lupus erythematosus (SLE) since their occurrence correlates with renal involvement and, possibly, with nephritic activity. We aimed to evaluate the prevalence of anti-C1q antibodies in patients with SLE, with and without renal involvement, and to correlate these markers' presence and levels with the activity of the disease and nephropathy. We studied 61 patients with SLE, 40 of whom had biopsy-proven lupus nephritis; 35 patients with other connective tissue diseases; and 54 healthy controls. In addition, 18 lupus nephritis patients were followed up during the disease time course. Anti-C1q antibodies were mea…

BiopsySLELupus nephritisEnzyme-Linked Immunosorbent AssaySystemic lupus erythematosuAnti-DNA antibodieSeverity of Illness IndexGeneral Biochemistry Genetics and Molecular BiologyFollow-Up StudieNephropathyCohort StudiesHistory and Philosophy of Scienceimmune system diseasesAutoimmune diseasePrevalencemedicineHumansLupus Erythematosus SystemicConnective Tissue DiseasesGlomerulonephritiskin and connective tissue diseasesRenal flareConnective Tissue DiseaseAutoantibodiesAutoimmune diseaseBiochemistry Genetics and Molecular Biology (all)Systemic lupus erythematosusbusiness.industryLupus nephritiComplement C1qGeneral NeuroscienceAutoantibodyGlomerulonephritisBiomarkermedicine.diseaseLupus NephritisAutoantibodieAntibodies Anti-IdiotypicItalyAntibodies AntinuclearImmunologyAnti-C1q antibodieCohort StudiebusinessNephritisBiomarkersFollow-Up StudiesHumanAnti-SSA/Ro autoantibodiesAnnals of the New York Academy of Sciences
researchProduct